Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2014-01-06 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
关于审计机构名称变更的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the change of the audit firm's name, explicitly stating it is not a change of the audit institution itself. It contains no financial data, no audit report, and no detailed financial statements. The document is an official announcement about an audit-related administrative change. Given its short length (552 characters) and content, it fits best as a Regulatory Filing (RNS) rather than a full Audit Report (AR) or Annual Report (10-K).
2014-01-06 Chinese
第八届监事会第三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of the company regarding the approval of the 2013 third quarter report and a capital increase proposal for a subsidiary. It includes voting results and confirms compliance with legal and regulatory requirements. The document is short (671 characters) and primarily announces the approval of a quarterly report rather than containing the full report itself. Therefore, it is not the actual Interim/Quarterly Report (IR) but an announcement related to it. Given the nature of the content and the short length, this fits best under Regulatory Filings (RNS) as a general regulatory announcement about the supervisory board's resolutions and approvals.
2013-10-25 Chinese
独立董事关于关联交易的事前认可意见
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors providing their prior approval opinion on a related party transaction concerning capital increase in a subsidiary. It references regulatory guidelines and company rules but does not contain financial statements or detailed financial data. The document is short (512 characters) and primarily serves as an official opinion or certification related to governance and compliance rather than a full report or announcement of financial results. It does not fit into categories like Annual Report, Interim Report, or Audit Report. It is not a voting result announcement or a management change notice. The content aligns best with a Regulatory Filing (RNS) as it is a formal regulatory compliance document related to corporate governance and related party transactions.
2013-10-25 Chinese
独立董事关于关联交易事项的独立意见
Board/Management Information Classification · 95% confidence The document is a statement of independent directors providing their opinion on a related party transaction, referencing compliance with regulatory guidance and company bylaws. It is not a full report but an opinion related to a board matter. This fits best under Board/Management Information (MANG) as it concerns board-level decisions and opinions on corporate governance matters, specifically related to a transaction approval.
2013-10-25 Chinese
关于对子公司增资的关联交易公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a related party transaction involving capital increase in a subsidiary company. It details the transaction background, parties involved, amounts, and approvals by the board and independent directors. There are no financial statements or comprehensive financial data presented, nor is this a full report like an annual or interim report. The document is a formal disclosure of a corporate action related to financing and capital structure changes. This fits the definition of a Capital/Financing Update (CAP). The document length is 2579 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the classification is CAP with high confidence.
2013-10-25 Chinese
第八届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board meeting of the company, including approval of the company's 2013 third quarter report and a capital increase for a subsidiary. It is titled as a board meeting resolution announcement and contains voting results. It does not contain the full third quarter report itself, only the approval of it. The document is short (571 characters) and serves as a formal announcement of board decisions rather than a full financial report. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2013-10-25 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.